Cerevel Therapeutics (CERE) Stock Forecast, Price Target & Predictions
CERE Stock Forecast
Cerevel Therapeutics stock forecast is as follows: an average price target of $33.50 (represents a -25.49% downside from CERE’s last price of $44.96) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
CERE Price Target
CERE Analyst Ratings
Cerevel Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 06, 2022 | - | J.P. Morgan | $40.00 | $28.01 | 42.81% | -11.03% |
Aug 15, 2022 | Graig Suvannavejh | Mizuho Securities | $27.00 | $34.86 | -22.55% | -39.95% |
Cerevel Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $44.96 | $44.96 | $44.96 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Dec 07, 2023 | Piper Sandler | - | Neutral | Downgrade |
Sep 26, 2022 | Wells Fargo | - | Overweight | Initialise |
Cerevel Therapeutics Financial Forecast
Cerevel Therapeutics Revenue Forecast
Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | 1 | 1 | 1 | 2 | 2 | 2 | 5 |
Surprise % | - | - | - | - | - | - | - |
Cerevel Therapeutics EBITDA Forecast
Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 2 | 2 | 5 |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Cerevel Therapeutics Net Income Forecast
Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 2 | 2 | 5 |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-138.02M | $-132.58M | $-130.76M | $-154.37M | $-131.67M | $-137.12M | $-119.50M |
High Forecast | $-138.02M | $-132.58M | $-130.76M | $-154.37M | $-131.67M | $-101.65M | $-119.50M |
Low Forecast | $-138.02M | $-132.58M | $-130.76M | $-154.37M | $-131.67M | $-167.85M | $-119.50M |
Surprise % | - | - | - | - | - | - | - |
Cerevel Therapeutics SG&A Forecast
Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 2 | 2 | 5 |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Cerevel Therapeutics EPS Forecast
Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 2 | 2 | 5 |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.76 | $-0.73 | $-0.72 | $-0.85 | $-0.72 | $-0.76 | $-0.66 |
High Forecast | $-0.76 | $-0.73 | $-0.72 | $-0.85 | $-0.72 | $-0.56 | $-0.66 |
Low Forecast | $-0.76 | $-0.73 | $-0.72 | $-0.85 | $-0.72 | $-0.92 | $-0.66 |
Surprise % | - | - | - | - | - | - | - |
Cerevel Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
HOWL | Werewolf Therapeutics | $2.34 | $12.00 | 412.82% | Buy |
DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
IGMS | IGM Biosciences | $12.30 | $25.00 | 103.25% | Buy |
APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
SWTX | SpringWorks Therapeutics | $37.42 | $67.33 | 79.93% | Buy |
CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
TVTX | Travere Therapeutics | $13.48 | $21.60 | 60.24% | Buy |
TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
CERE Forecast FAQ
Is Cerevel Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Cerevel Therapeutics (CERE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of CERE's total ratings.
What is CERE's price target?
Cerevel Therapeutics (CERE) average price target is $33.5 with a range of $27 to $40, implying a -25.49% from its last price of $44.96. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cerevel Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CERE stock, the company can go down by -25.49% (from the last price of $44.96 to the average price target of $33.5), down by -11.03% based on the highest stock price target, and down by -39.95% based on the lowest stock price target.
Can Cerevel Therapeutics stock reach $70?
CERE's average twelve months analyst stock price target of $33.5 does not support the claim that Cerevel Therapeutics can reach $70 in the near future.
What are Cerevel Therapeutics's analysts' financial forecasts?
CERE's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-543M (high $-507M, low $-573M), average SG&A $0 (high $0, low $0), and average EPS is $-2.988 (high $-2.793, low $-3.157).